Mankind Pharma: India Business to Recover, BSV Integration on Track. Maintain ADD

Equity Bottom-Up

235 Views21 May 2025 04:54

Broker

Mankind Pharma (Mankind) has witnessed a moderation in its India business in 9MFY25 to single digits (~9% YoY ex-BSV) from mid-double-digit growth in the past (13% CAGR over FY20-24)

What is covered in the Full Insight:

Introduction to Mankind Pharma's Current Position
Factors Affecting Recent Growth
Future Growth Projections and BSV Integration
Financial Implications and Market Expectations
Key Risks and Investment Perspective

HDFC Securities

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 24-minute read)

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream